FDA Adds Boxed Warning to CAR T-Cell Therapies, but Says Benefits Outweigh Risks of Secondary Cancers

被引：8
|
作者：
Suran, Melissa
机构：
来源：
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION | 2024年 / 331卷 / 10期
关键词：
D O I：
10.1001/jama.2024.1011
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
This Medical News article discusses the US Food and Drug Administration's new boxed warning requirement and investigation of secondary malignancies after CAR T-cell therapy.
引用
收藏
页码：889 / 889
页数：3
相关论文
共 10 条
  • [1] Balancing the risks and benefits of CAR T-cell therapy
    不详
    LANCET HAEMATOLOGY, 2024, 11 (03): : e169 - e169
  • [2] FDA investigating safety risks in CAR T-cell recipients
    Nelson, Roxanne
    LANCET, 2023, 402 (10418): : 2181 - 2181
  • [3] CAR T-cell therapies: risk of secondary malignancy of T-cell origin
    Reactions Weekly, 2024, 2019 (1) : 1 - 1
  • [4] Rarity & Risk of Secondary Hematologic Neoplasms after CAR T-cell Therapies
    Hamilton, Mark P.
    Alizadeh, Ash A.
    TRANSPLANTATION AND CELLULAR THERAPY, 2024, 30 (10): : 936 - 938
  • [5] The underlying mechanism of chimeric antigen receptor (CAR)-T cell therapy triggering secondary T-cell cancers: Mystery of the Sphinx?
    Zhou, Zhaokai
    Zhang, Ge
    Xu, Yudi
    Yang, Shuai
    Wang, Jiaojiao
    Li, Zhengrui
    Peng, Fu
    Lu, Qiong
    CANCER LETTERS, 2024, 597
  • [6] The Current Landscape of Secondary Malignancies after CAR T-Cell Therapies: How Could Malignancies Be Prevented?
    Bouziana, Stella
    Bouzianas, Dimitrios
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2024, 25 (17)
  • [7] COST-EFFECTIVENESS OF CHIMERIC ANTIGEN RECEPTOR (CAR) T-CELL THERAPIES FOR BLOOD CANCERS: A SYSTEMATIC REVIEW
    Patel, N.
    Farid, S.
    Gomes, M.
    VALUE IN HEALTH, 2023, 26 (06) : S118 - S118
  • [8] Redefining chimeric antigen receptor T-cell (CAR-T) regulation: China's responses to address secondary cancer risks of CAR-T therapy
    Tan, Ruirong
    Li, Rui
    Dai, Meng-Yuan
    Liu, Miao
    Zhao, Junning
    JOURNAL OF HEMATOLOGY & ONCOLOGY, 2024, 17 (01)
  • [9] Risks and Benefits of Chimeric Antigen Receptor T-Cell (CAR-T) Therapy in Cancer: A Systematic Review and Meta-Analysis
    Grigor, Emma J. M.
    Fergusson, Dean
    Kekre, Natasha
    Montroy, Joshua
    Atkins, Harold
    Seftel, Matthew D.
    Daugaard, Mads
    Presseau, Justin
    Thavom, Kednapa
    Hutton, Brian
    Holt, Robert A.
    Lalu, Manoj M.
    TRANSFUSION MEDICINE REVIEWS, 2019, 33 (02) : 98 - 110
  • [10] CAR T-cell therapy in relapsed/refractory diffuse large B-cell lymphoma: physician preferences trading off benefits, risks and time to infusion
    Boeri, Marco
    Purdum, Anna G.
    Sutphin, Jessie
    Hauber, Brett
    Kaye, James A.
    FUTURE ONCOLOGY, 2021, 17 (34) : 4697 - 4709
1